Abstract
Systemic vasculitis are heterogeneous, complex and disabling disorders. Following the previous annual reviews of this series, this paper gives a brief overview on current knowledge about recent literature on small- and large-vessel systemic vasculitis, with a specific focus on pathogenetic and clinical aspects, novel possible disease-related biomarkers and current and future therapies that are in the pipeline.
MeSH terms
-
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy
-
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology
-
Antirheumatic Agents / therapeutic use
-
Churg-Strauss Syndrome / drug therapy
-
Churg-Strauss Syndrome / immunology
-
Cryoglobulinemia / complications
-
Cryoglobulinemia / drug therapy
-
Cryoglobulinemia / immunology*
-
Giant Cell Arteritis / drug therapy
-
Giant Cell Arteritis / immunology
-
Granulomatosis with Polyangiitis / drug therapy
-
Granulomatosis with Polyangiitis / immunology
-
Hepatitis C, Chronic / complications
-
Hepatitis C, Chronic / immunology*
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Microscopic Polyangiitis / drug therapy
-
Microscopic Polyangiitis / immunology
-
Systemic Vasculitis / drug therapy
-
Systemic Vasculitis / etiology
-
Systemic Vasculitis / immunology*
-
Takayasu Arteritis / drug therapy
-
Takayasu Arteritis / immunology
Substances
-
Antirheumatic Agents
-
Immunosuppressive Agents